SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
We would like to inform that one of the Designated Person of Shilpa Medicare Limited ('Company'), have traded in the equity shares of the Company in violation of the Code read with SEBI (Prohibition of Insider Trading) Regulations, 2015 ('PIT Regulations'). SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Please find enclosed a Certificate dated 03 October 2022 for the quarter and half Year ended 30 September, 2022, certifying that the details of securities dematerialized / rematerialized during the aforesaid period were maintained by "M/s. Kfin Technologies Limited" (SEBI Registration No. INR000000221), the Registrar and Share Transfer Agent of ShiIpa Medicare Limited. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated 28th September 2022 regarding outcome of the 35th Annual General Meeting, please find enclosed newspaper publication of e-voting results of the 35th Annual General Meeting held on 28th September 2022 in 'businessline' - all edition (English) on 04th October 2022. SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
We wish to inform you that the 35th Annual General Meeting (AGM) of the Company and the business mentioned in the Notice convening the AGM were transacted. In this regard, please find enclosed the following; 1. Submission of voting results in compliance with the provisions of regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 2. Submission of Report of Scrutinizer dated 28th September, 2022 in compliance with the provisions of section 108 of the Companies Act, 2013 and Rule 20 (4) (xii) of the Companies (Management and Administration), Rules 2014. SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window
we would like to inform you that pursuant to Code of Conduct for Regulating, Monitoring and Reporting Trading by Designated Persons and their Immediate Relatives, the Trading Window for dealing in the securities of the Company shall remain closed for all designated persons and their immediate relatives as covered under the said Code with effect from 01st October, 2022 till 48 hours after the declaration of Un-audited Financial Results of the Company for the quarter/half year ended 30th September, 2022. Please note that the date of the Board Meeting to be held for the consideration of Un-audited Financial Results of the Company for the quarter/half year ended 30th September, 2022 shall be communicated in due course of time. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Change in Directorate
Cessation of Director on account of completion of tenure SHILPA MEDICARE LTD. - 530549 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Pursuant to Regulation 30 of the Listing Regulations, we are submitting herewith the details regarding the proceedings of 35th Annual General Meeting ("AGM") of the Company (enclosed herewith as Annexure) held on Wednesday, 28th September 2022 at 11.30 a.m. and concluded at 12.06 p.m. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) at the Registered Office of the Company. The Insta-Poll commenced after the conclusion of AGM for 15 minutes. Summary of proceedings as required under Regulation 30, Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations annexed hereto. SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited, Analytical Services Division, Nacharam, Hyderabad, Telangana Has Received US FDA Clearance (EIR) For The Facility
This is to inform you that the Company's Analytical Services Division situated at Nacharam, Hyderabad, Telangana has received US FDA clearance (EIR) for the inspection performed during 26 Apr 2022 to 29 Apr 2022. This is the first US FDA inspection of this facility. The facility is identified as testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited (Parent Organization) and its agreed parties. The FDA clearance on the facility will enable the company to test and release batches into US from this facility. This facility, after appropriate submissions, can also be used for testing and releasing batches into Europe and other markets of the world. The facility is involved in analytical testing of drug products (Release & Stability), drug substances, raw materials & packing materials. It is also engaged in analytical method validations, method transfers and conduct of other miscellaneous analytical studies. SHILPA MEDICARE LTD. - 530549 - Shilpa'S Tranexamic Acid Spray (Hemostatic Spray) Is Approved By CDSCO (Dcgi)
Shilpa would like to announce its successful innovation of first in world topical hemostatic spray of Tranexamic Acid has received CDSCO approval. This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic... SHILPA MEDICARE LTD. - 530549 - Intimation U/R 30 Of The SEBI (LODR) Regulations 2015- Reg.
This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Tenofovir Alafenamide Tablets, 25 mg on 15 Sep 2022. The ANDA was filed as 'First to File' submission on NCE -1 date. Tenofovir Alafenamide Tablets, 25 mg is a generic equivalent of reference listed drug (RLD) Vemlidy(r) tablets, of Gilead Sciences Inc. used in the treatment of chronic hepatitis B virus infection as recommended in the label approved by FDA. According to IQVIA MAT Q2 2022 data, the US market for Tenofovir Alafenamide Tablets, 25 mg is approximately US$ 498.14 Million. This is for your information and doing the needful.